One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is “staffing up” ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Isomorphic Labs advances towards human clinical trials for AI-designed drugs, marking a pivotal moment in pharmaceutical ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune.Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...